Reuters: Moderna and Merck announced that the personalized vaccine against cancer reduced the risk of recurrence or death by melanoma by 42%
As broadcast by the news agency Reuters, Moderna and Merck announced on Thursday that the anti-cancer vaccine based on mRNA technology, combined with Merck's widely used immunotherapy, reduced the risk of death or recurrence of melanoma in a large clinical trial by 42%. This result may open [...]





